Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Immune globulin for COVID-19 infections

Trial Profile

A clinical study of Immune globulin for COVID-19 infections

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2020

At a glance

  • Drugs Immune globulin (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Apr 2020 According to a Grifols media release, the company is leading this trial in collaboration with the U.S. Food and Drug Administration (FDA) and other health agencies.
    • 30 Mar 2020 New trial record
    • 25 Mar 2020 According to a Grifols media release, the company will is collaborating with certain hospitals in the design of this study.

Trial Overview

Purpose

This trial will evaluate the efficacy of Immune globulin for the treatment of COVID-19 infections.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Grifols

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Immune globulinPrimary Drug
-
-

Immune-globulin

Trial History

Event Date Event Type Comment
21 Apr 2020 Other trial event According to a Grifols media release, the company is leading this trial in collaboration with the U.S. Food and Drug Administration (FDA) and other health agencies. Updated 22 Apr 2020
30 Mar 2020 New trial record New trial record Updated 30 Mar 2020
25 Mar 2020 Other trial event According to a Grifols media release, the company will is collaborating with certain hospitals in the design of this study. Updated 30 Mar 2020

References

  1. Grifols. Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19. Media-Rel 2020;.

    Media Release
  2. Grifols. Grifols maintains its operational levels and continues to reinforce its commitment to society. Media-Rel 2020;.

    Media Release
Back to top